These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
188 related articles for article (PubMed ID: 28385551)
1. Down syndrome: age-dependence of PiB binding in postmortem frontal cortex across the lifespan. LeVine H; Spielmann HP; Matveev S; Cauvi FM; Murphy MP; Beckett TL; McCarty K; Lott IT; Doran E; Schmitt F; Head E Neurobiol Aging; 2017 Jun; 54():163-169. PubMed ID: 28385551 [TBL] [Abstract][Full Text] [Related]
2. Post-mortem analyses of PiB and flutemetamol in diffuse and cored amyloid-β plaques in Alzheimer's disease. Ikonomovic MD; Buckley CJ; Abrahamson EE; Kofler JK; Mathis CA; Klunk WE; Farrar G Acta Neuropathol; 2020 Oct; 140(4):463-476. PubMed ID: 32772265 [TBL] [Abstract][Full Text] [Related]
3. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Ikonomovic MD; Klunk WE; Abrahamson EE; Mathis CA; Price JC; Tsopelas ND; Lopresti BJ; Ziolko S; Bi W; Paljug WR; Debnath ML; Hope CE; Isanski BA; Hamilton RL; DeKosky ST Brain; 2008 Jun; 131(Pt 6):1630-45. PubMed ID: 18339640 [TBL] [Abstract][Full Text] [Related]
4. A distinct subfraction of Aβ is responsible for the high-affinity Pittsburgh compound B-binding site in Alzheimer's disease brain. Matveev SV; Spielmann HP; Metts BM; Chen J; Onono F; Zhu H; Scheff SW; Walker LC; LeVine H J Neurochem; 2014 Nov; 131(3):356-68. PubMed ID: 24995708 [TBL] [Abstract][Full Text] [Related]
5. Amyloid β accumulation assessed with ¹¹C-Pittsburgh compound B PET and postmortem neuropathology. Hatsuta H; Takao M; Ishii K; Ishiwata K; Saito Y; Kanemaru K; Arai T; Suhara T; Shimada H; Shinotoh H; Tamaoka A; Murayama S Curr Alzheimer Res; 2015; 12(3):278-86. PubMed ID: 25731622 [TBL] [Abstract][Full Text] [Related]
6. Cognitive decline and brain amyloid-β accumulation across 3 years in adults with Down syndrome. Hartley SL; Handen BL; Devenny D; Mihaila I; Hardison R; Lao PJ; Klunk WE; Bulova P; Johnson SC; Christian BT Neurobiol Aging; 2017 Oct; 58():68-76. PubMed ID: 28715661 [TBL] [Abstract][Full Text] [Related]
7. Assessment of beta-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh Compound B. Leinonen V; Alafuzoff I; Aalto S; Suotunen T; Savolainen S; Någren K; Tapiola T; Pirttilä T; Rinne J; Jääskeläinen JE; Soininen H; Rinne JO Arch Neurol; 2008 Oct; 65(10):1304-9. PubMed ID: 18695050 [TBL] [Abstract][Full Text] [Related]
8. Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain. Klunk WE; Lopresti BJ; Ikonomovic MD; Lefterov IM; Koldamova RP; Abrahamson EE; Debnath ML; Holt DP; Huang GF; Shao L; DeKosky ST; Price JC; Mathis CA J Neurosci; 2005 Nov; 25(46):10598-606. PubMed ID: 16291932 [TBL] [Abstract][Full Text] [Related]
9. Using positron emission tomography and Carbon 11-labeled Pittsburgh Compound B to image Brain Fibrillar β-amyloid in adults with down syndrome: safety, acceptability, and feasibility. Landt J; D'Abrera JC; Holland AJ; Aigbirhio FI; Fryer TD; Canales R; Hong YT; Menon DK; Baron JC; Zaman SH Arch Neurol; 2011 Jul; 68(7):890-6. PubMed ID: 21403005 [TBL] [Abstract][Full Text] [Related]
10. Comparing amyloid-β plaque burden with antemortem PiB PET in autosomal dominant and late-onset Alzheimer disease. Chen CD; Joseph-Mathurin N; Sinha N; Zhou A; Li Y; Friedrichsen K; McCullough A; Franklin EE; Hornbeck R; Gordon B; Sharma V; Cruchaga C; Goate A; Karch C; McDade E; Xiong C; Bateman RJ; Ghetti B; Ringman JM; Chhatwal J; Masters CL; McLean C; Lashley T; Su Y; Koeppe R; Jack C; Klunk WE; Morris JC; Perrin RJ; Cairns NJ; Benzinger TLS Acta Neuropathol; 2021 Oct; 142(4):689-706. PubMed ID: 34319442 [TBL] [Abstract][Full Text] [Related]
11. Amyloid imaging with carbon 11-labeled Pittsburgh compound B for traumatic brain injury. Hong YT; Veenith T; Dewar D; Outtrim JG; Mani V; Williams C; Pimlott S; Hutchinson PJ; Tavares A; Canales R; Mathis CA; Klunk WE; Aigbirhio FI; Coles JP; Baron JC; Pickard JD; Fryer TD; Stewart W; Menon DK JAMA Neurol; 2014 Jan; 71(1):23-31. PubMed ID: 24217171 [TBL] [Abstract][Full Text] [Related]
13. Imaging brain amyloid in nondemented young adults with Down syndrome using Pittsburgh compound B. Handen BL; Cohen AD; Channamalappa U; Bulova P; Cannon SA; Cohen WI; Mathis CA; Price JC; Klunk WE Alzheimers Dement; 2012 Nov; 8(6):496-501. PubMed ID: 23102120 [TBL] [Abstract][Full Text] [Related]
14. In vivo amyloid imaging in autopsy-confirmed Parkinson disease with dementia. Burack MA; Hartlein J; Flores HP; Taylor-Reinwald L; Perlmutter JS; Cairns NJ Neurology; 2010 Jan; 74(1):77-84. PubMed ID: 20038776 [TBL] [Abstract][Full Text] [Related]
15. Brain-predicted age in Down syndrome is associated with beta amyloid deposition and cognitive decline. Cole JH; Annus T; Wilson LR; Remtulla R; Hong YT; Fryer TD; Acosta-Cabronero J; Cardenas-Blanco A; Smith R; Menon DK; Zaman SH; Nestor PJ; Holland AJ Neurobiol Aging; 2017 Aug; 56():41-49. PubMed ID: 28482213 [TBL] [Abstract][Full Text] [Related]
16. Amyloid imaging of dutch-type hereditary cerebral amyloid angiopathy carriers. Schultz AP; Kloet RW; Sohrabi HR; van der Weerd L; van Rooden S; Wermer MJH; Moursel LG; Yaqub M; van Berckel BNM; Chatterjee P; Gardener SL; Taddei K; Fagan AM; Benzinger TL; Morris JC; Sperling R; Johnson K; Bateman RJ; ; Gurol ME; van Buchem MA; Martins R; Chhatwal JP; Greenberg SM Ann Neurol; 2019 Oct; 86(4):616-625. PubMed ID: 31361916 [TBL] [Abstract][Full Text] [Related]
17. Early AD pathology in a [C-11]PiB-negative case: a PiB-amyloid imaging, biochemical, and immunohistochemical study. Ikonomovic MD; Abrahamson EE; Price JC; Hamilton RL; Mathis CA; Paljug WR; Debnath ML; Cohen AD; Mizukami K; DeKosky ST; Lopez OL; Klunk WE Acta Neuropathol; 2012 Mar; 123(3):433-47. PubMed ID: 22271153 [TBL] [Abstract][Full Text] [Related]
18. Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Johnson KA; Gregas M; Becker JA; Kinnecom C; Salat DH; Moran EK; Smith EE; Rosand J; Rentz DM; Klunk WE; Mathis CA; Price JC; Dekosky ST; Fischman AJ; Greenberg SM Ann Neurol; 2007 Sep; 62(3):229-34. PubMed ID: 17683091 [TBL] [Abstract][Full Text] [Related]
19. The Down syndrome brain in the presence and absence of fibrillar β-amyloidosis. Annus T; Wilson LR; Acosta-Cabronero J; Cardenas-Blanco A; Hong YT; Fryer TD; Coles JP; Menon DK; Zaman SH; Holland AJ; Nestor PJ Neurobiol Aging; 2017 May; 53():11-19. PubMed ID: 28192686 [TBL] [Abstract][Full Text] [Related]
20. Sequence of deposition of heterogeneous amyloid beta-peptides and APO E in Down syndrome: implications for initial events in amyloid plaque formation. Lemere CA; Blusztajn JK; Yamaguchi H; Wisniewski T; Saido TC; Selkoe DJ Neurobiol Dis; 1996 Feb; 3(1):16-32. PubMed ID: 9173910 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]